[Betablockers and skin (author's transl)].
Up to now betablockers, with the exception of erythermalgia, have been rarely used as therapeutic agents in dermatology. However, cutaneous drug reactions are numerous. A review of the literature about practolol cutaneous effects and their possible mechanisms has shown that a great variety of clinical states can be encountered. All betablockers have been known to produce harmful side effects, although less frequently. In conclusion, the description of each new case of cutaneous drug reaction probably due to betablocker must be assessed.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000906:Antibodies; D005128:Eye Diseases / Q000139:chemically induced / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000209:etiology; D009092:Mucous Membrane / Q000187:drug effects; D011565:Psoriasis / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced* / Q000188:drug therapy; D013577:Syndrome
D000319:Adrenergic beta-Antagonists; D000906:Antibodies
Bêtabloquants et peau.